Innovative therapeutics

Investors

SEC Filings

NASDAQBMRN
FormDescriptionDateFormat
4Statement of changes in beneficial ownership of securitiesMar 6, 2018View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesMar 6, 2018View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesMar 6, 2018View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesMar 6, 2018View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesMar 6, 2018View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesMar 6, 2018View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesFeb 28, 2018View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesFeb 28, 2018View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesFeb 28, 2018View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesFeb 28, 2018View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesFeb 28, 2018View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesFeb 28, 2018View HTMLDownload DOCDownload PDF
SC 13G/AAmendment to a previously filed SC 13GFeb 27, 2018View HTMLDownload DOCDownload PDFDownload XLS
10-KAnnual report which provides a comprehensive overview of the company for the past yearFeb 26, 2018View HTMLDownload DOCDownload PDFDownload XLSView XBRLDownload XBRL
8-KReport of unscheduled material events or corporate eventFeb 22, 2018View HTMLDownload DOCDownload PDFDownload XLS
4/AAmendment to a previously filed 4Feb 20, 2018View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesFeb 20, 2018View HTMLDownload DOCDownload PDF
5Annual filing director officer or owner of more than ten percent.Feb 14, 2018View HTMLDownload DOCDownload PDF
5Annual filing director officer or owner of more than ten percent.Feb 14, 2018View HTMLDownload DOCDownload PDF
5Annual filing director officer or owner of more than ten percent.Feb 14, 2018View HTMLDownload DOCDownload PDF
5Annual filing director officer or owner of more than ten percent.Feb 14, 2018View HTMLDownload DOCDownload PDF
SC 13G/AAmendment to a previously filed SC 13GFeb 14, 2018View HTMLDownload DOCDownload PDF
SC 13G/AAmendment to a previously filed SC 13GFeb 14, 2018View HTMLDownload DOCDownload PDF
SC 13G/AAmendment to a previously filed SC 13GFeb 13, 2018View HTMLDownload DOCDownload PDF
SC 13G/AAmendment to a previously filed SC 13GFeb 12, 2018View HTMLDownload DOCDownload PDFDownload XLS
1-25      26-50      51-75      76-100      101-125      126-137

BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU, LEMS

Products

Brineura™
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information